CD40L-Adjuvanted DNA/Modified Vaccinia Virus Ankara Simian Immunodeficiency Virus (SIV) Vaccine Enhances Protection against Neutralization-Resistant Mucosal SIV Infection

Suefen Kwa, Shanmugalakshmi Sadagopal, Xiaoying Shen, Jung Joo Hong, Sailaja Gangadhara, Rahul Basu, Blandine Victor, Smita S. Iyer, Celia C. LaBranche, David C. Montefiori,

Journal of Virology · 2015 · 31 citations · 8 references

DOIFull text

Open access

Concepts

Abstract

Here, we show that a CD40L-adjuvanted DNA/modified vaccinia virus Ankara (MVA) simian immunodeficiency virus (SIV) vaccine enhances protection against a pathogenic neutralization-resistant mucosal SIV infection, improves long-term viral control, and prevents AIDS. Analyses of serum IgG antibodies to linear peptides of SIV Env revealed a strong response to V2, with targeting of fewer epitopes in the immunodominant region of gp41 (gp41-ID) and the V1 region as a correlate for enhanced protection. Greater expansion of antiviral CD8 T cells in the gut correlated with long-term viral control.

References

8